Ashley S Margol

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3850743/publications.pdf

Version: 2024-02-01

41 papers	1,046 citations	623734 14 h-index	434195 31 g-index
42 all docs	42 docs citations	42 times ranked	2153 citing authors

#	Article	IF	Citations
1	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	7.7	168
2	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science Translational Medicine, 2016, 8, 366ra161.	12.4	144
3	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential Highâ€Dose Chemotherapy. Pediatric Blood and Cancer, 2016, 63, 1527-1534.	1.5	94
4	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. Clinical Cancer Research, 2015, 21, 1457-1465.	7.0	92
5	Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genetics, 2014, 207, 358-364.	0.4	81
6	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro-Oncology, 2016, 18, 126-131.	1.2	69
7	Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents. Antimicrobial Agents and Chemotherapy, 2015, 59, 3090-3097.	3.2	56
8	Pediatric Brain Tumor Cell Lines. Journal of Cellular Biochemistry, 2015, 116, 218-224.	2.6	50
9	Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget, 2019, 10, 551-557.	1.8	44
10	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. Journal of Neuro-Oncology, 2017, 133, 119-128.	2.9	32
11	PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. Clinical Cancer Research, 2014, 20, 827-836.	7.0	29
12	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro-Oncology, 2020, 22, 944-954.	1.2	25
13	Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.. Journal of Clinical Oncology, 2020, 38, 10525-10525.	1.6	24
14	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. Neuro-Oncology, 2020, 22, 785-796.	1.2	18
15	Primary diffuse leptomeningeal glioneuronal tumors of the central nervous system: Report of three cases and review of literature. Pediatric Hematology and Oncology, 2020, 37, 248-258.	0.8	17
16	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro-Oncology, 2022, 24, 1964-1975.	1.2	15
17	A genome-wide association study on medulloblastoma. Journal of Neuro-Oncology, 2020, 147, 309-315.	2.9	10
18	A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Childrenâ€™s Oncology Group. Journal of Neuro-Oncology, 2018, 140, 575-582.	2.9	9

#	Article	IF	Citations
19	Clinical and neuropsychological outcome of pediatric nonâ€midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children's Hospital Los Angeles experience. Pediatric Blood and Cancer, 2019, 66, e27983.	1.5	9
20	Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner. Journal of Physical Education and Sports Management, 2018, 4, a002576.	1.2	8
21	Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. Journal of Neuro-Oncology, 2018, 138, 199-207.	2.9	7
22	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. Journal of Neuro-Oncology, 2019, 145, 375-383.	2.9	7
23	IDHâ€mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature. Brain Pathology, 2021, 31, e12959.	4.1	7
24	Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo ¹H-MR Spectroscopy. American Journal of Neuroradiology, 2019, 40, 872-877.	2.4	6
25	Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics. Pediatric Blood and Cancer, 2020, 67, e28516.	1.5	5
26	Palliative Care Options for a Young Adult Patient with a Diffuse Intrinsic Pontine Glioma. Cureus, 2017, 9, e1580.	0.5	5
27	Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series. Cureus, 2020, 12, e10804.	0.5	4
28	Multiâ€institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatric Blood and Cancer, 2021, 68, e29172.	1.5	3
29	Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. Neuro-Oncology Advances, 2021, 3, vdab037.	0.7	3
30	Comparison of Vincristine Pharmacokinetics (PK) in Adolescent/Young Adult (AYA) Versus Younger Patients Defined By Tanner Stage during Treatment for Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3725-3725.	1.4	2
31	Influenza vaccine immunization in a pediatric oncology ambulatory practice.. Journal of Clinical Oncology, 2013, 31, 139-139.	1.6	1
32	MEDB-86. A re-induction regimen for children with recurrent medulloblastoma. Neuro-Oncology, 2022, 24, i126-i127.	1.2	1
33	Multiâ€institutional analysis of central nervous system germ cell tumors in patients with Down syndrome. Pediatric Blood and Cancer, 2022, 69, .	1.5	1
34	AT-02MR SPECTROSCOPY AND METABOLIC SUBTYPES OF ATYPICAL TERATOID RHABDOID TUMORS IN CHILDREN. Neuro-Oncology, 2016, 18, iii1.1-iii1.	1.2	0
35	AT-23ENCOURAGING SURVIVAL OF PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) ATYPICAL TERATOID AND RHABDOID TUMOR (AT/RT) TREATED AS PER CHILDREN'S ONCOLOGY GROUP ACNS0333 STUDY: A SINGLE-INSTITUTION EXPERIENCE. Neuro-Oncology, 2016, 18, iii6.3-iii6.	1.2	0
36	NU-12THE USE OF AROMATHERAPY TO REDUCE CHEMOTHERAPY-INDUCED NAUSEA IN CHILDREN WITH CANCER; A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL. Neuro-Oncology, 2016, 18, iii137.2-iii137.	1.2	0

#	Article	IF	Citations
37	MBCL-49. PROGNOSTIC SIGNIFICANCE OF MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IN CHILDREN RECEIVING IRRADIATION-SPARING REGIMENS. Neuro-Oncology, 2018, 20, i128-i128.	1.2	0
38	NURS-09. INTRODUCTION OF A WELLNESS PROGRAM FOR PEDIATRIC NEURO-ONCOLOGY PROVIDERS. Neuro-Oncology, 2020, 22, iii422-iii422.	1.2	0
39	OTHR-09. CENTRAL DIABETES INSIPIDUS: A RARE UNREPORTED SIDE EFFECT OF TEMOZOLOMIDE IN PEDIATRICS. Neuro-Oncology, 2020, 22, iii423-iii424.	1.2	0
40	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. Neuro-Oncology, 2020, 22, iii332-iii332.	1.2	0
41	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. Neuro-Oncology, 2022, 24, i117-i117.	1.2	0